Company Encyclopedia
View More
name
RIGHTONGENE
688217.SH
Shanghai Rightongene Biotechnology Co., Ltd. engages in the research and development, production, and sale of molecular diagnosis of infectious diseases in China. The company offers self-operated reagents, purchased preparations, scientific research services, and testing services for blood diseases, solid tumors, infectious diseases and lymphoma. Shanghai Rightongene Biotechnology Co., Ltd.
1.568 T
688217.SHMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
D
BiotechnologyIndustry
Industry Ranking80/80
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE0.00%D
    • Profit Margin-14.14%D
    • Gross Margin75.64%A
  • Growth ScoreE
    • Revenue YoY-22.99%E
    • Net Profit YoY-424.31%E
    • Total Assets YoY0.00%C
    • Net Assets YoY0.00%C
  • Cash ScoreE
    • Cash Flow Margin-707.35%E
    • OCF YoY-22.99%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio4.17%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    RIGHTONGENE: Xiong Hui resigns from the positions of Chairman and General Manager

    RIGHTONGENE announced on September 9th that the board of directors recently received a written resignation letter submitted by Xiong Hui. Xiong Hui applied to resign from the positions of chairman, director, general manager, and core technical personnel of the company for personal reasons. After resigning, Xiong Hui will hold other positions within the company and will still be one of the actual controllers of the company, complying with relevant laws and regulations as well as the commitments made by herself

    Zhitong·
    SH
    688217
    -5.44%
    Zhitong·
    SH
    688217
    -5.44%

    Shanghai Rightongene Biotechnology's Boards Elects Chairman

    Shanghai Rightongene Biotechnology Co Ltd :SAYS BOARDS ELECTS GAO SHANG AS CHAIRMAN

    Reuters·
    SH
    688217
    -5.44%
    Reuters·
    SH
    688217
    -5.44%

    RIGHTONGENE released its 2024 annual performance, with a net loss attributable to the parent company of 15.7645 million yuan, turning from profit to loss

    According to the Zhitong Finance APP, RIGHTONGENE released its annual report for 2024, stating that the company's operating revenue for 2024 was 242 million yuan, a year-on-year decrease of 6.16%; the net loss attributable to shareholders of the listed company was 15.7645 million yuan, turning from profit to loss; the net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 19.2476 million yuan, turning from profit to loss; the basic loss per share was 0.28 yuan/share

    Zhitong·
    SH
    688217
    -5.44%
    Zhitong·
    SH
    688217
    -5.44%

    RIGHTONGENE's net loss for the year 2024 is 14.4636 million yuan

    According to the Zhitong Finance APP, RIGHTONGENE released its performance preliminary report for 2024. The company's total operating revenue for 2024 was 242 million yuan, a year-on-year decrease of 6.33%; the net loss attributable to the parent company's owners was 14.4636 million yuan; the net loss attributable to the parent company's owners after deducting non-recurring gains and losses was 17.9663 million yuan; the basic loss per share was 0.26 yuan

    Zhitong·
    SH
    688217
    -5.44%
    Zhitong·
    SH
    688217
    -5.44%

    Shanghai Rightongene Biotechnology Receives 1.8 Million Yuan in Government Subsidies

    Shanghai Rightongene Biotechnology received 1.8 million yuan in government subsidies, according to a Tuesday filing with the Shanghai bourse. Shares of the in-vitro diagnosis products manufacturer were down 1% in recent trade.

    Trading View·
    SH
    688217
    -5.44%
    Trading View·
    SH
    688217
    -5.44%